Key points are not available for this paper at this time.
myocarditis myositis I mmune checkpoint inhibitors (ICIs) provide frequent durable responses and improve patient overall survival in numerous cancers. Blocking immune checkpoints (Programmed cell Death 1 PD-1/PD-ligand 1 or Cytotoxic T Lymphocyte-Associated Protein 4 CTLA-4) to restore antitumor immune response may also break immune tolerance to self-antigens and induce specific immune-related adverse events (irAEs). It is interesting to note that the initial descriptions of ICIassociated myocarditis described 25% of concomitant myositis.
Anquetil et al. (Tue,) studied this question.